Thursday, April 30th, 2009
BIG news in the plastic surgery field. The FDA approved the drug Dysport (otherwise known as Reloxin) today for the treatment of fine lines in the glabella (between the brows). This is the first bona-fide competitor to Botox, as it is also a Botulinum Toxin Type A.
I’ve mentioned Reloxin in this blog before, as well as on the Rachael Ray show a couple months ago. Plastic surgeons (and patients) hope that this can act as an economic bailout for the 4 million Americans who pay several hundreds of dollars for each Botox treatment. I think we would all welcome a price war between Allergan (makers of Botox) and Medicis (makers of Dysport).
How does Dysport compare to Botox? Other than the fact that they are both Botulinum Toxin Type A, it’s difficult to tell. However, if Dysport is priced competitively with Botox and has similar efficacy, we may see a multi-billion dollar product reaching your plastic surgeons’ offices in the next 30-60 days. Stay tuned!
Source: Globe Newswire
Thanks for reading.
Michigan-based Plastic Surgeon
Anthony Youn, M.D.